Losartan Potassium Tablet
Product Images NDC 72162-2506

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72162-2506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (F205834f 7a27 4968 9605 90a2c53ce7e9 01)

Chemical structure of Losartan Potassium, showing its molecular arrangement including key ring structures and potassium ion (K+).*

FDA Label Image

Figure 1 (F205834f 7a27 4968 9605 90a2c53ce7e9 02)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium and Atenolol. The x-axis represents study months and the y-axis shows the percentage of patients with the primary endpoint. Losartan Potassium shows a lower percentage of patients reaching the endpoint compared to Atenolol, with an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Figure 2 (F205834f 7a27 4968 9605 90a2c53ce7e9 03)

Line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol (dotted line) and Losartan potassium (solid line). The graph shows adjusted risk reduction data with a 25% reduction and statistical significance (p=0.001), indicating lower stroke incidence for Losartan potassium over time.*

FDA Label Image

Figure 3 (F205834f 7a27 4968 9605 90a2c53ce7e9 04)

A forest plot chart comparing hazard ratios for Losartan Potassium versus Atenolol based on event rates in various patient subgroups. It presents primary composite and stroke (fatal/non-fatal) event rates, stratified by age, gender, race, ischemic heart status, diabetes, and cardiovascular disease history, with confidence intervals and hazard ratios indicating which treatment is favored.*

FDA Label Image

Figure 4 (F205834f 7a27 4968 9605 90a2c53ce7e9 05)

A line graph showing the percentage of patients with an event over 48 months, comparing Losartan Potassium and placebo groups. The graph indicates a risk reduction of 16.1% with a p-value of 0.022 favoring Losartan Potassium.*

FDA Label Image

Image (F205834f 7a27 4968 9605 90a2c53ce7e9 06)

FDA Label Image

Company Logo (F205834f 7a27 4968 9605 90a2c53ce7e9 07)

FDA Label Image

Label (Lbl721622506)

Losartan Potassium Tablets USP 25 mg oral tablets packaging label showing a count of 30 tablets. The label includes the NDC 72162-2506 and indicates the product is repackaged by Bryant Ranch Prepack and manufactured by Unichem Laboratories Ltd. Storage instructions and a QR code for dosage information are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.